Stockscreener 앱 받기
66.85
10.06%
6.11
시간 외 거래:
67.14
0.29
+0.43%
전일 마감가:
$60.74
열려 있는:
$61.25
하루 거래량:
26,065
Relative Volume:
0.49
시가총액:
$218.87M
수익:
$18.47M
순이익/손실:
$-1.05M
주가수익비율:
-190.29
EPS:
-0.3513
순현금흐름:
$-33.87M
1주 성능:
+11.42%
1개월 성능:
-18.20%
6개월 성능:
-15.45%
1년 성능:
+138.84%
1일 변동 폭
$61.05
$67.29
1주일 범위
$58.30
$67.29
52주 변동 폭
$27.00
$97.97
Sol Gel Technologies Ltd Stock (SLGL) Company Profile
Compare SLGL vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLGL
Sol Gel Technologies Ltd
|
66.85 | 218.87M | 18.47M | -1.05M | -33.87M | -0.3513 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sol Gel Technologies Ltd Stock (SLGL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-19 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2019-12-31 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-31 | 재확인 | JMP Securities | Mkt Outperform |
Sol Gel Technologies Ltd 주식(SLGL)의 최신 뉴스
Sol-Gel’s Patidegib Gel Nears Key Milestone With Completed Phase 3 Gorlin Syndrome Study - TipRanks
Sol-Gel completes phase 3 trial for Gorlin syndrome treatment - Investing.com
Sol-Gel completes phase 3 trial for Gorlin syndrome treatment By Investing.com - Investing.com Nigeria
SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - finance.yahoo.com
Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome - marketscreener.com
Sol-Gel Technologies Reaches Last-Patient Milestone in Phase 3 Gorlin Syndrome Trial - TipRanks
Sol-Gel Technologies (SLGL) hits key Phase 3 Gorlin milestone - Stock Titan
A skin-cancer trial reaches its final visit. Sol-Gel expects results in late November. - Stock Titan
Opaleye Management Inc. Adds Sol-Gel Technologies Ltd (SLGL) -- Shares Look 968% Overvalued on GF Value - GuruFocus
Opaleye Management Increases Stake in Sol-Gel Technologies with 9,976 Shares Bought (NASDAQ: SLGL) - Kalkine Media
Sol-Gel Technologies: Phase 3 Gorlin Results Could Be The Next Major Catalyst - RTTNews
Sol Gel Technologies Ltd (NASDAQ: SLGL) Stock Price, News & Analysis - Kalkine
CollPlant Biotechnologies LtdADR Peer Comparison – Compare with Others - Value Research
Opaleye Management Inc. Adds to Sol-Gel Technologies Ltd (SLGL) - GuruFocus
Sol-Gel Technologies (SLGL) Consolidates Near $70.1 Within Established Trading RangeMoney Flow - dars.gov.et
UroGen Pharma Ltd. (URGN) Peer Comparison – Compare with Others - Value Research
Enlivex Therapeutics Ltd.ADR Peer Comparison – Compare with Others - Value Research
SLGL Q2 2026 Earnings: Loss Narrows Sharply on 52% EPS Beat, Yet Shares Slip 5.18%EPS Growth Rate - careplusvn.com
LifeSci Capital Maintains Sol-Gel Technologies(SLGL.US) With Buy Rating, Maintains Target Price $195 - Moomoo
Sol-Gel (SLGL) Snapshot: Closes 0.97% Lower at $77.73 for the Current Session; Price Setup: the $73.84 to $81.62 Range Remains in Focus in the Latest ReadingSuperTrend - vinanet.vn
Sol Gel Tech earnings beat by $2.20, revenue fell short of estimates - Investing.com India
Sol-Gel Technologies: Runway To Fund Cash Requirements Into 1Q 2028 >SLGL - Moomoo
Sol-Gel reports $0.6M Q2 revenue as SGT-610 trial advances - grafa.com
symbol__ Stock Quote Price and Forecast - CNN
Sol-Gel Technologies Releases Q2 2026 Financial Results - AlphaStreet
Sol-Gel Technologies Posts Q2 Loss as Pivotal Gorlin Syndrome Trial Advances Toward Late-2026 Readout - TipRanks
Sol-Gel Technologies (NASDAQ:SLGL) Posts Quarterly Earnings Results, Beats Expectations By $1.23 EPS - MarketBeat
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
Sol-Gel Technologies (NASDAQ: SLGL) sees cash runway into Q1 2028 - Stock Titan
SLGL Q1 2026 Earnings: Narrower Loss Beats Estimate, Shares Slip 2.83%Annual Report - dars.gov.et
Opaleye Management Reports Acquisition of Sol-Gel Technologies Shares - Kalkine Media
Sol-Gel Technologies (SLGL) Projected to Announce Quarterly Earnings on Friday - MarketBeat
ELDN Stock Price and Chart — NASDAQ:ELDN - TradingView
Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Sol-Gel Technologies Q1 2026 Earnings: Narrower Loss Delivers 30.2% EPS Beat, Yet Shares Slip 6.04%Earnings Call Q&A - dars.gov.et
Sol Gel Technologies Ltd (SLGL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sol-Gel Technologies (SLGL) Edges Lower by 0.79% as Shares Hold Above $79.78 SupportAscending Triangle - careplusvn.com
Sol-Gel Technologies (SLGL) Edges Lower as Stock Tests Key Support ZoneTurnaround Stocks - vinanet.vn
Sol Gel Technologies Ltd (SLGL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
SLGL|Sol Gel Technologies Ltd|Price:79.230|Chg%:-0.600 - TradingKey
Sol Gel Technologies Ltd (SLGL) Cash Flow - TradingKey
Sol Gel Technologies Ltd (SLGL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sol Gel Technologies Ltd (SLGL) Institutional Confidence - TradingKey
TradingKey - TradingKey
Sol-Gel Technologies (SLGL) Climbs 2.17% as Bulls Test Resistance Near $86RVOL Spike - dars.gov.et
Sol-Gel Technologies Ltd. Revenue Breakdown – NASDAQ:SLGL - tradingview.com
Sol-Gel Technologies Ltd. Revenue Breakdown – FWB:4SG - TradingView
Sol Gel Technologies Ltd (SLGL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SLGL Q2'26 Earnings: revenue estimate is 75.00K USD - tradingview.com
What the $10B Crinetics Deal & $2.9B Soleno Acquisition Might Say About Palatin’s Rare-Obesity Opportunit - Benzinga
Opaleye Management Inc. Increases Stake in Sol-Gel Technologies Ltd - GuruFocus
Sol Gel Technologies Ltd (SLGL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):